Navigation Links
Yale test detects early stage ovarian cancer with 99 percent accuracy
Date:2/12/2008

Researchers at Yale School of Medicine have developed a blood test with enough sensitivity and specificity to detect early stage ovarian cancer with 99 percent accuracy.

Results of this new study are published in the February 15 issue of the journal Clinical Cancer Research. The results build on work done by the same Yale group in 2005 showing 95 percent effectiveness of a blood test using four proteins.

The ability to recognize almost 100 percent of new tumors will have a major impact on the high death rates of this cancer, said Mor. We hope this test will become the standard of care for women having routine examinations.

Epithelial ovarian cancer is the leading cause of gynecologic cancer deaths in the United States and three times more lethal than breast cancer. It is usually not diagnosed until its advanced stages and has come to be known as the silent killer.

This new phase II clinical trial led by Gil Mor, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale, included 500 patients; 350 healthy controls and 150 ovarian cancer patients. Mor and colleagues validated the previous research and used a new platform called multiplex technology to simplify the test into one single reaction using very small amounts of serum from the blood. The new platform uses six protein biomarkers instead of four, increasing the specificity of the test from 95 to 99.4 percent. The team looked for the presence of specific proteins and quantified the concentration of those proteins in the blood.

The Early Detection Research Network (EDRN) of the National Cancer Institute (NCI) independently evaluated the results of the test.

This is the most sensitive and specific test currently available, said Mor. Previous tests recognized 15 to 20 percent of new tumors. Proteins from the tumors were the only biomarkers used to test for ovarian cancer. That is okay when you have big masses of tumors, but it is not applicable in very early phases of the tumor. Testing the proteins produced by the body in response to the presence of the tumor as well as the proteins the tumors produce, helped us to create a unique picture that can detect early ovarian cancer.

Mor and colleagues have begun a phase III evaluation in a multi-center clinical trial. In collaboration with EDRN/NCI and Laboratories Corporation of America (LabCorp), they are testing close to 2,000 patients.

The test is available at Yale through the Discovery to Cure program. Yale has licensed the test to three companies: Lab Corp in the United States, Teva in Israel and SurExam in China.


'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert  

Related medicine news :

1. Test Detects Sensitivity to HIV Drug
2. McMaster test detects the most prevalent respiratory viruses
3. CT colonography detects wide-range of extracolonic abnormalities in elderly patients
4. Blood protein detects lung cancer, even at earliest stage
5. New technique detects specific chromosomal damage, may indicate lung cancer risk
6. New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment
7. JCI online early table of contents: Feb. 7, 2008
8. New study suggests link between environmental toxins and early onset puberty in girls
9. A Reminder to Parents: Early Dental Visits Essential to Childrens Health
10. Rheumatoid arthritis sends many into early retirement
11. Early detection critical in treating pediatric thyroid cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Yale test detects early stage ovarian cancer with 99 percent accuracy
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by ... require dental technicians to be certified or obtain continuing education. To increase patient ... “What’s In Your Mouth?” campaign to inform dentists and patients about the possible ...
(Date:2/7/2016)... Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... in recognition of National Wear Red Day. National Wear Red Day is the ... stroke in women. Heart disease and stroke cause 1 in 3 deaths among women ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud to ... This event brings together top non-profit leaders, ultimate organizations, and coaches from around the ... Iani, Bay Area Disc Program Director of Youth and Education, describes this year YUCC ...
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and Kevin ... of a new DRTV campaign with Belly Bands. , Having a dog is great—except ... to puppy pads and find nothing works, get Belly Bands, the easiest way ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... part of a major growth and expansion initiative, Dune Medical ... Chmura as President of Dune Inc., its U.S. division. ... experience in the medical device space will play a large ... --> --> In her new ... and operational functions in the U.S. She is tasked with ...
(Date:2/8/2016)... Mich. , Feb. 8, 2016  The University ... announced today that, as part of the ... one of the first hospitals in the U.S. to ... Karin Muraszko , M.D., U-M,s chair of neurosurgery. ... of neurosurgery. --> The BrightMatter technology ...
(Date:2/8/2016)...  Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today announced ... December 31, 2015, the Company achieved revenue of $8,195,839, a ... quarter in fiscal 2015. --> ... year 2016 was $2,068,635, or $.03 per share, up 265% ... in the Q2 of fiscal year 2015. Gross margin for ...
Breaking Medicine Technology: